iC9-GD2-CAR-VZV-CTL

iC9-GD2-CAR-VZV-CTL is an investigational autologous CAR-T cell therapy designed for the treatment of GD2-positive malignancies, including neuroblastoma and osteosarcoma. The therapy utilizes T cells that are naturally specific for the Varicella Zoster Virus (VZV-CTLs), which are then genetically modified using a retroviral vector to express a chimeric antigen receptor (CAR) targeting the disialoganglioside GD2. The CAR construct incorporates an antigen-binding domain derived from the 14g2a antibody along with CD28 and OX40 costimulatory endodomains to enhance T-cell activation, expansion, and survival. A unique feature of this therapy is the use of VZV-specific cells, which allows the potential for T-cell persistence to be boosted by the administration of a standard VZV vaccine. To mitigate potential toxicity, the cells also express an inducible caspase 9 (iC9) safety switch, which can be activated by a chemical inducer of dimerization to trigger rapid apoptosis of the modified T cells.

Other names

GD2-T cellsGD-2-T cellsGD 2-T cellsiC9-GD2-CAR-VZV-specific T cellsiC-9-GD2-CAR-VZV-specific T cellsiC 9-GD2-CAR-VZV-specific T cellsGD2-CAR-VZV-CTLGD-2-CAR-VZV-CTLGD 2-CAR-VZV-CTL